📰 Eric Dobmeier News
Page 3 - Eric Dobmeier News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eric Dobmeier. Real-time updates on events, politics, business and more.
May 11, 2023
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) – Equities research analysts at Wedbush issued their Q1 2024 earnings per share (EPS) estimates for shares of Chinook Therapeutics in a research note issued to investors on Wednesday, May 10th. Wedbush analyst L. Chico anticipates that the company will post earnings of ($0.81) per share for the […]
May 10, 2023
Chinook Therapeutics (NASDAQ:KDNY – Get Rating) announced its quarterly earnings results on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.03), Briefing.com reports. Chinook Therapeutics had a negative net margin of 3,065.68% and a negative return on equity of 40.61%. The business had revenue […]
May 10, 2023
Chinook Therapeutics (NASDAQ:KDNY – Get Rating) issued its quarterly earnings data on Tuesday. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.03), Briefing.com reports. Chinook Therapeutics had a negative net margin of 3,065.68% and a negative return on equity of 40.61%. The firm had revenue of $1.83 million […]
April 29, 2023
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) CEO Eric Dobmeier sold 23,800 shares of the stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $21.58, for a total transaction of $513,604.00. Following the transaction, the chief executive officer now directly owns 302,338 shares in the […]
April 21, 2023
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) fell 4.1% on Thursday following insider selling activity. The company traded as low as $21.42 and last traded at $21.48. 106,804 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 544,286 shares. The stock had previously closed at $22.41. Specifically, Director […]
April 16, 2023
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) has been assigned a consensus rating of “Buy” from the nine brokerages that are covering the company, MarketBeat reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued a report on the stock in the last […]
April 13, 2023
SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development...
January 31, 2023
Allspring Global Investments Holdings LLC bought a new stake in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 3,310 shares of the company’s stock, valued at approximately $65,000. Several other […]
November 4, 2022
The initial response to de novo subcutaneous (SC) BION-1301 treatment in Cohort 2 is highly consistent with Cohort 1 across both mechanistic biomarkers and...
May 28, 2022
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) CEO Eric Dobmeier purchased 5,000 shares of the stock in a transaction on Wednesday, May 25th. The shares were purchased at an average cost of $13.03 per share, for a total transaction of $65,150.00. Following the acquisition, the chief executive officer now directly owns 205,880 shares of the […]